| Brittany Ard, LPN | |
|
172 Julia Dr, Avondale, LA 70094-2825 | |
| (504) 360-4164 | |
| Not Available |
| Full Name | Brittany Ard |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 172 Julia Dr, Avondale, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194478578 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 20140880 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brittany Ard, LPN 172 Julia Dr, Avondale, LA 70094-2825 Ph: (504) 360-4164 | Brittany Ard, LPN 172 Julia Dr, Avondale, LA 70094-2825 Ph: (504) 360-4164 |
News Archive
Apparently scientists have discovered that a natural component of cannabis suppresses the appetite and that discovery may lead to a new class of drugs for treating obesity.
A team of Columbia University Medical Center (CUMC) researchers, led by Nobel laureate Eric R. Kandel, MD, has found that deficiency of a protein called RbAp48 in the hippocampus is a significant contributor to age-related memory loss and that this form of memory loss is reversible.
OrthoAccel Technologies, Inc. has announced commercial plans for the United Kingdom that entail considerable business activity and economic impact. Last year, the Company hired a Director of Sales based in Wales. Recently, a full-market UK release of the AcceleDent System was reported. In conjunction with this product introduction at the British Orthodontic Conference, OrthoAccel has publicized plans to host a private lecture and reception to provide scientific data and education to doctors on this new technology that shortens orthodontic treatment time.
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
› Verified 1 days ago